Scalper1 News
From Saturday through Tuesday, reps from drugmakers around the world will be gathering in New Orleans to present data on their blood-disease drugs at the American Society of Hematology conference. Among them are two top-rated big-cap biotechs, and though the abstracts are already out, the details of their reports have the potential to move stocks. Celgene (CELG) on Sunday afternoon will offer long-awaited data from its MM020 trial, which is meant Scalper1 News
Scalper1 News